Evidence map›Paper›PMID 42919386›Full record

ArticleJournal of translational medicine2026

Single-cell transcriptomics reveals macrophage-neutrophil crosstalk in Haematitum-induced lung injury associated with gut dysbiosis.

Min Lu, Hangjie Zhu, Yifan Peng, Shamei Zhu, Bisheng Huang, Yan Cao

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Min Lu *School of Pharmacy, Hubei University of Chinese Medicine, Wuhan, 430065, China.
Hangjie Zhu *School of Pharmacy, Hubei University of Chinese Medicine, Wuhan, 430065, China.
Yifan PengSchool of Pharmacy, Hubei University of Chinese Medicine, Wuhan, 430065, China.
Shamei ZhuSchool of Pharmacy, Hubei University of Chinese Medicine, Wuhan, 430065, China.
Bisheng HuangSchool of Pharmacy, Hubei University of Chinese Medicine, Wuhan, 430065, China.
Yan CaoSchool of Pharmacy, Hubei University of Chinese Medicine, Wuhan, 430065, China. caoyan1999@hbucm.edu.cn.ORCID http://orcid.org/0000-0003-1114-482X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHaematitum is a mineral-based traditional Chinese medicine widely used in clinical applications. Both the Chinese Materia Medica and modern research indicate that it exhibits lung toxicity and should not be administered over prolonged periods. The precise mechanism underlying this toxicity, however, remains incompletely understood. PURPOSE: This study aims to systematically elucidate the toxic mechanism of lung injury induced by Haematitum administration, emphasizing the central role of the gut-lung axis in this process.

methodsThe mouse model of lung injury induced by Haematitum was established. A combination of 16S rRNA sequencing, untargeted metabolomics, and single-cell RNA sequencing was utilized to comprehensively analyze alterations in the intestinal microbiota, lung tissue metabolism, and lung cell atlas. The pharmacological validation was conducted by administering PPARγ agonists and TNF-α inhibitors. Furthermore, the detoxification effect of its classical combination with Inula japonica Thunb. was also evaluated.

resultsHigh-dose Haematitum disrupted the intestinal barrier and induced dysbiosis. Metabolites from the gut microbiota entered the bloodstream and exerted a pathogenic effect. Correlation analysis showed that gut microbiota dysbiosis is strongly associated with the pulmonary glycerophospholipid metabolic pathway. Results from single-cell sequencing and macrophage/TNF-α colocalization experiments indicated that the macrophages' PPAR signaling pathway was inhibited, inactivating their anti-inflammatory function and triggering the release of inflammatory factors such as TNF-α. Acting as a key messenger, TNF-α activated the TNF signaling pathway in neutrophils, driving them to acquire a highly destructive phenotype. The synergy between macrophages and neutrophils ultimately provoked inflammation and cell apoptosis in lung tissue. Pharmacological intervention of the PPARγ/TNF-α axis can effectively reverse cellular abnormalities and significantly alleviate lung injury. The combination with Inula japonica Thunb. also reduced lung toxicity, and components within this herb are predicted to act as natural PPARγ agonists.

conclusionsThis study has revealed a potential toxic mechanism. The intestinal barrier in mice was compromised, with an increase in the relative abundance of Klebsiella, entry of microbial metabolites into the bloodstream, and disruption of glycerophospholipid metabolism in the lungs, which in turn resulted in dysfunction of pulmonary immune cells. It clarifies that the core mechanism of Haematitum-induced lung injury lies in inhibiting the PPAR signaling pathway in macrophages and activating the TNF signaling pathway in neutrophils. Administering Haematitum at a common dose or in combination with Inula japonica Thunb. mitigates these safety risks. These findings advance understanding of the toxicology of mineral-based medicines and provide a reference for the safe clinical application of these traditional Chinese medicines.

Indexed as

DysbiosisGene Expression ProfilingLung InjuryMacrophagesNeutrophilsSingle-Cell AnalysisTranscriptomeAnimalsGastrointestinal MicrobiomeLungMaleMiceMice, Inbred C57BLPPAR gammaRNA, Ribosomal, 16SSignal TransductionPPAR gammaRNA, Ribosomal, 16STumor Necrosis Factor-alphaGlycerophospholipid metabolismHaematitumKlebsiellaMacrophageNeutrophilToxic mechanism

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.